Final Medicare rule to curb doctor-administered drug prices covers only four firms, delivering far less savings than proposed
read at STAT ↗RegulatoryNegative
The Trump administration released a final rule intended to lower Medicare prices for drugs given in doctors' offices.
The rule applies only to four pharmaceutical companies, a far narrower scope than originally expected.
According to STAT, the projected savings under the final rule are about 96% lower than the savings estimated in the initial proposal.
The limited impact has drawn criticism from advocates who hoped for broader price reductions.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more”
read at STAT ↗680 words · retrieved 49m ago
comments(0)
5-min edit window · permanent after that